Patient resources

As someone being treating for a serious condition like acromegaly, you may need support from time to time. Always remember that you are not alone in having acromegaly, and you always have resources to take advantage of.

Learn about insurance coverage, pharmacies that carry Somatuline^® Depot (lanreotide) Injection, and the Reimbursement Hotline.

Read about support organizations for people treating acromegaly, national advocacy organizations, and Web sites where you can find more information.

Find the meanings of any terms used in this Web site that you may not understand in the glossary.

Prescribing information for Somatuline Depot

Get complete information about Somatuline Depot in the Full Prescribing Information.

How does Somatuline Depot work?

By mimicking a natural hormone, Somatuline Depot helps your body control acromegaly. Learn more about how Somatuline^® Depot works.

Who should take Somatuline Depot?

Last year it helped over 6000 people with acromegaly. See who should take Somatuline Depot.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

2008 Tercica Legal Notices | Privacy Statement